Search for: "Daubert v. Merrell Dow Pharmaceuticals, Inc." Results 161 - 180 of 247
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Jul 2014, 7:24 am by Kristin Casler
Merrell Dow Pharmaceuticals, Inc. (509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 [1993]).Admissibility of Securities Expert Witness:In a memorandum opinion, Judge F. [read post]
15 Sep 2014, 10:45 pm by Kristin Casler
Merrell Dow Pharmaceuticals, Inc. (509 U.S. 579, 592, 113 S.Ct. 2786, 125 L.Ed.2d 469 [1993]), the panel said. [read post]
15 Sep 2014, 10:45 pm by Kristin Casler
Merrell Dow Pharmaceuticals, Inc. (509 U.S. 579, 592, 113 S.Ct. 2786, 125 L.Ed.2d 469 [1993]), the panel said. [read post]
7 Sep 2020, 11:33 am by Stuart Kaplow
Merrell Dow Pharmaceuticals, Inc., the Supreme Court held that Federal Rule of Evidence superseded Frye’s general acceptance test. [read post]
1 May 2008, 11:21 am
Beretta USA, Inc., No. 05-6942-cv (2d Cir. [read post]
16 Jun 2017, 7:00 am by Anjelica Cappellino
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), the Supreme Court case upon which the standard for expert testimony is based, seeks to exclude the testimony of an expert witness that is not relevant or reliable. [read post]
11 May 2020, 1:09 am by Schachtman
That was the tradition that stood in active need of reform when Daubert was decided in 1993. [read post]
9 Oct 2018, 5:00 am by Anjelica Cappellino
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), there are several factors that should be considered by a court when determining the admissibility of expert testimony. [read post]
3 Jan 2015, 3:47 pm by Robert Kreisman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) and granted BNSF’s motion for summary judgment. [read post]